-
TCAIM Regulates Mitochondrial Metabolism via OGDH Protein Re
2026-04-25
This study identifies the mitochondrial DNAJC co-chaperone TCAIM as a specific regulator of α-ketoglutarate dehydrogenase (OGDH) protein levels, revealing a novel post-translational control mechanism that suppresses mitochondrial metabolism. The findings provide mechanistic insight into mitochondrial proteostasis, suggesting new directions for metabolic research.
-
Practical Guide to the AO/PI Double Staining Kit (K2238)
2026-04-24
The AO/PI Double Staining Kit provides a rapid, dual-fluorescent method for distinguishing viable, apoptotic, and necrotic cells in a single assay. This kit is ideal for cell viability, apoptosis, and necrosis detection workflows, but should not be used for applications lacking fluorescent microscopy or flow cytometry capabilities.
-
Imatinib Hydrochloride: Precision Tyrosine Kinase Inhibition
2026-04-24
Imatinib hydrochloride (STI571 hydrochloride) is a gold-standard tyrosine kinase inhibitor that enables targeted pathway interrogation in cancer models. This guide demystifies advanced experimental setups, dual-action inhibition strategies, and troubleshooting techniques, empowering researchers to leverage APExBIO’s Imatinib for robust, reproducible oncogenic signaling studies.
-
Helper-Polymer Nanoparticles Enable Stable Lung-Specific mRN
2026-04-23
This study introduces five-element nanoparticles (FNPs) as a novel platform for delivering mRNA specifically to the lung with unprecedented stability after lyophilization and storage at 4 °C. The findings provide a foundation for more accessible, robust mRNA-based therapies targeting pulmonary diseases, with implications for research and clinical implementation.
-
TAK1 Stabilizes YAP to Promote Self-Renewal in Gastric CSCs
2026-04-23
This study uncovers how TGFβ-activated kinase 1 (TAK1) stabilizes yes-associated protein (YAP), enhancing the self-renewal and oncogenic potential of gastric cancer stem cells (GCSCs). By elucidating the TAK1–YAP axis, the work provides a mechanistic basis for targeting GCSC maintenance and addresses chemoresistance challenges in gastric cancer.
-
AR Heterogeneity Drives Distinct Prostate Cancer Therapy Res
2026-04-22
Li et al. (2018) reveal that heterogeneity in androgen receptor (AR) expression underpins divergent responses to castration and enzalutamide in prostate cancer. Their integrative approach links AR status to tumorigenic properties and defines BCL-2 as a key therapeutic target, informing tailored treatment strategies.
-
Rifampin in Research: Data-Driven Solutions for Reliable Ass
2026-04-22
This article delivers scenario-based guidance on overcoming real-world lab challenges using Rifampin (SKU B2021) as a benchmark rifamycin antibiotic. Drawing on protocol optimization, data interpretation, and vendor selection, it equips researchers with actionable, evidence-backed strategies for bacterial resistance mechanism research and transcriptional regulation studies.
-
Gut Microbiota Therapies and Neuroinflammation in Hepatic En
2026-04-21
This study rigorously compared Bifidobacterium and fecal microbiota transplantation (FMT) for modulating neuroinflammation in a chronic hepatic encephalopathy (HE) rat model, using [18F]PBR146 PET imaging. The findings highlight a region-specific neuroinflammatory response to Bifidobacterium but not FMT, informing future research on gut-liver-brain axis interventions.
-
Cy7 NHS Ester: Practical Protocols for Near-Infrared Protein
2026-04-21
Cy7 NHS ester is a sulfonated, hydrophilic near-infrared dye optimized for covalent labeling of amino groups on proteins and peptides, addressing the challenge of labeling delicate biomolecules in fully aqueous conditions. It is best suited for in vitro and in vivo imaging workflows where high water solubility and minimal dye aggregation are essential. This reagent is not recommended for applications requiring long-term dye solution storage or labeling in strongly denaturing environments.
-
Advancing In Vitro Drug Response Evaluation in Cancer Resear
2026-04-20
Schwartz's dissertation introduces a rigorous framework to distinguish between proliferative arrest and cell death in in vitro cancer drug assays, revealing that most anti-cancer agents exert complex, time-dependent effects on both processes. This nuanced approach enables researchers to more accurately interpret drug efficacy and optimize experimental models for translational oncology.
-
PR-619: Precision DUB Inhibition for Advanced Epigenetic Res
2026-04-20
Explore how PR-619, a potent deubiquitylating enzymes inhibitor, enables precise control of the ubiquitination pathway for cutting-edge cancer and neurodegeneration studies. Discover unique assay insights and learn how PR-619 bridges protein homeostasis with epigenetic modulation.
-
Triptolide (PG490): Translational Insights from Tight Juncti
2026-04-19
Explore how Triptolide (PG490) uniquely connects tight junction biology with cancer cell invasion inhibition and immunomodulation. This in-depth analysis leverages new mechanistic evidence and practical protocol recommendations for advanced research.
-
Rotigotine hydrochloride: Reliable Solutions for PD Research
2026-04-18
This evidence-driven article addresses real-world laboratory challenges in dopaminergic signaling research and Parkinson's disease models using Rotigotine hydrochloride (SKU A3777). Drawing on validated literature and workflow scenarios, we provide quantitative guidance and protocol tips for maximizing reproducibility, sensitivity, and data integrity with this dopamine D2/D3 receptor agonist.
-
Erastin: Ferroptosis Inducer for Precision Cancer Biology
2026-04-17
Erastin is a validated ferroptosis inducer targeting RAS/BRAF-mutant tumor cells, acting via system Xc⁻ inhibition and redox disruption. Its specificity and reproducibility make it a benchmark reagent in ferroptosis research and cancer biology. Key protocol parameters and mechanistic insights support its widespread use in oxidative stress assays, with applications and limitations clearly defined.
-
SC 79: A Potent Cytosolic Akt Activator for Neuroprotection
2026-04-16
SC 79 is a validated small molecule Akt activator that selectively enhances cytosolic Akt phosphorylation, driving neuroprotection in ischemic stroke and enabling advanced Akt signaling pathway research. Its unique mechanism and pharmacokinetics make it a critical tool for both neuroscience and metabolic studies.